X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-expanded-use-beigenes-blood-cancer-drug-2024-03-07/
https://www.prnewswire.com/news-releases/nektar-and-collaborators-present-preclinical-data-on-nktr-255-combined-with-obinutuzumab-in-poster-presentation-at-the-65th-american-society-of-hematology-ash-annual-meeting-302011865.html
https://endpts.com/roche-withdraws-ema-application-for-cancer-medicine-gazyvaros-new-indication/
https://www.onclive.com/view/long-term-rosewood-data-confirm-efficacy-of-zanubrutinib-plus-obinutuzumab-in-r-r-follicular-lymphoma
https://www.onclive.com/view/venetoclax-atezolizumab-obinutuzumab-elicits-durable-responses-in-richter-transformation
https://investor.seagen.com/press-releases/news-details/2023/Phase-3-Trial-of-ADCETRIS-brentuximab-vedotin-with-Modified-Chemo-Regimen-Shows-Non-Inferiority-with-Unprecedented-3-Year-Progression-Free-Survival-of-94.9-vs-Less-Tolerable-International-Standard-of-Care-in-Advanced-Classical-Hodgkin-Lymphoma/default.aspx
https://www.onclive.com/view/ibrutinib-obinutuzumab-venetoclax-triplet-elicits-sustained-clinical-benefit-in-mantle-cell-lymphoma
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125486
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125486
https://www.fiercepharma.com/pharma/planning-all-oral-once-daily-regimen-jj-gets-ema-backing-imbruvica-venetoclax-combination
http://www.pharmafile.com/news/637320/smc-accepts-chemotherapy-free-venclyxto-leukaemia-treatment
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125486
https://finance.yahoo.com/news/tg-therapeutics-falls-30-ceo-173034141.html
https://www.globenewswire.com/news-release/2021/10/14/2313911/0/en/Roche-s-Gazyvaro-shorter-90-minute-infusion-time-approved-in-Europe-for-people-with-previously-treated-or-untreated-follicular-lymphoma.html
https://www.cancertherapyadvisor.com/home/news/conference-coverage/eha2021-virtual-congress/chronic-leukemia-cll-ibrutinib-venetoclax-therapy-improve-outcome/
http://www.pharmafile.com/news/579996/janssen-cll-treatment-combination-sees-success-trials
https://news.abbvie.com/news/press-releases/imbruvica-ibrutinib-plus-venclextavenclyxto-venetoclax-combination-shows-superior-progression-free-survival-compared-to-chlorambucil-plus-obinutuzumab-in-first-line-chronic-lymphocytic-leukemia-cll-phase-3-glow-study.htm
http://www.pharmatimes.com/news/imbruvicavenclyxto_tops_gazyva_plus_chemo_in_first-line_cllsll_1371653
https://www.prnewswire.com/news-releases/cbmg-holdings-novel-anti-cd20-car-t-cell-therapy-shows-promising-safety-and-efficacy-in-relapsedrefractory-b-cell-non-hodgkin-lymphoma-patients-following-relapse-to-an-anti-cd19-car-t-therapy-301310049.html
https://www.prnewswire.com/news-releases/cbmg-holdings-novel-cd19cd20-bi-specific-car-t-cell-product-shows-early-promising-clinical-efficacy-and-favorable-safety-profile-in-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma-301310047.html
https://www.europeanpharmaceuticalreview.com/news/133345/nice-recommends-venetoclax-plus-obinutuzumab-chronic-lymphocytic-leukaemia-treatment/
https://www.prnewswire.com/news-releases/eha25virtual-advances-in-treatment-of-high-risk-chronic-lymphocytic-leukemia-301074647.html
http://www.pmlive.com/pharma_news/nice_backs_roches_gazyvaro,_pfizers_lorviqua_in_new_guidance_1340211
https://www.newswire.ca/news-releases/abbvie-receives-health-canada-approval-for-the-combination-of-venclexta-r-venetoclax-with-obinutuzumab-for-patients-with-previously-untreated-chronic-lymphocytic-leukemia-861483007.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125486
https://in.reuters.com/article/us-roche-lupus-nephritis/roche-bid-to-recycle-gayzva-for-lupus-nephritis-wins-fda-breakthrough-tag-idINKBN1W30OW
http://www.pharmatimes.com/news/fda_breakthrough_granted_for_roches_gazyva_1302030
http://www.pharmatimes.com/news/imbruvica_bags_eu_expansion_for_two_indications_1297443
http://www.pmlive.com/pharma_news/imbruvica_scores_expanded_use_in_europe_1297432
http://www.pharmatimes.com/news/az_bags_two_extensions_in_latest_chmp_decisions_1292946
https://www.fiercepharma.com/pharma/fda-lifts-partial-hold-venclexta-trial-multiple-myeloma-after-a-spate-deaths
https://www.fiercepharma.com/pharma/astrazeneca-s-calquence-sets-imbruvica-its-sights-promising-solo-cll-data
https://www.fiercepharma.com/pharma/roche-touts-phase-2-gazyva-data-lupus-nephritis-same-day-as-new-approval
https://www.fiercepharma.com/pharma/astrazeneca-s-calquence-treads-imbruvica-s-turf-second-ph3-cll-win
http://www.pharmatimes.com/news/abbvie,_roche_present_positive_venclyxto_results_at_asco_1289862
https://www.fiercepharma.com/pharma/abbvie-unveils-venclexta-data-scored-lightning-fast-cll-combo-nod
http://www.pmlive.com/pharma_news/venclexta_plus_gazyva_approval_adds_to_non-chemo_options_in_cll_1288261
http://www.pmlive.com/pharma_news/roche_files_venclexta_plus_gazyva_in_cll_1280889
https://www.biopharmadive.com/news/with-10th-fda-ok-imbruvica-further-expands-in-cll/547002/
http://www.pmlive.com/pharma_news/imbruvica_and_gazyvo_approved_in_first_non-chemo_cll_use_1276425
https://endpts.com/imbruvica-regimen-wins-fda-approval-as-first-non-chemotherapy-treatment-for-untreated-patients-with-common-form-of-leukemia/
https://www.reuters.com/article/us-abbvie-study-roche-hldg/abbvie-roche-combo-treatment-meets-main-goal-of-leukemia-trial-idUSKCN1N530I
http://www.pharmatimes.com/news/four_new_medicines_available_via_nhs_scotland_1251812
https://www.biospectrumasia.com/news/28/11606/chugai-nippon-shinyaku-bring-gazyva-in-japan.html
https://www.prnewswire.com/news-releases/european-hematology-association-overall-survival-benefit-of-obinutuzumab-over-rituximab-when-combined-with-chlorambucil-in-patients-with-chronic-lymphocytic-leukemia-and-comorbidities-685639192.html
Market Place
Share 
